Figure 2.
NMA results for response using COVID-19–adjusted data from ALPINE trial. ORs and Prob better for zanubrutinib vs comparators in high-risk patients.

NMA results for response using COVID-19–adjusted data from ALPINE trial. ORs and Prob better for zanubrutinib vs comparators in high-risk patients.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal